Hana Chen-Walden
Keine laufenden Positionen mehr
Profil
Hana Chen-Walden worked as the Director-International Regulatory Affairs at Covalent Group, Inc. from 2000 to 2003.
She then served as the Chief Medical Director at Boston Therapeutics, Inc. and as an Independent Director at BioXyTran, Inc. Dr. Chen-Walden holds a doctorate degree from Tel-Aviv University.
Ehemalige bekannte Positionen von Hana Chen-Walden
| Unternehmen | Position | Ende |
|---|---|---|
| BIOXYTRAN, INC. | Direktor/Vorstandsmitglied | 19.04.2024 |
| Covalent Group, Inc. | General Counsel | 01.01.2003 |
| NANOMIX CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Hana Chen-Walden
| Tel-Aviv University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BIOXYTRAN, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Boston Therapeutics, Inc.
 Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA. | Health Technology |
| Covalent Group, Inc. | Commercial Services |
